1. Scrip
  2. >>Business
  3. >>Strategy

Bavarian Nordic CEO Says Likely To Sell Imvamune Priority Review Voucher

 
• By Sten Stovall

Danish group believes its smallpox vaccine will get approved, generate a transferable priority review voucher, and replace the current US-licensed replicating smallpox vaccine ACAM2000.

Syringe
Bavavian Nordic Set To Reap Valuable Priority Review Voucher • Source: Shutterstock

FDA approval for Bavarian Nordic AS's smallpox vaccine Imvamune looks highly likely after the release earlier this month of successful Phase III trial data. Approval would generate a lucrative 'priority review voucher' which the Danish biotech would probably sell to generate liquidity, rather than use to accelerate a future review for another vaccine, its CEO told Scrip.

The Phase III clinical trial was led by the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and demonstrated the safety and efficacy of Bavarian Nordic's investigational, non-replicating smallpox vaccine

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: AstraZeneca CEO cautions Europe; Pfizer CEO optimistic on US tariffs, pricing; Merck & Co reassures on pipeline; Merck KGaA buys SpringWorks; and Akeso explains ivonescimab overall survival data.